Have a feature idea you'd love to see implemented?
Let us know!
SPRO Spero Therapeutics Inc
Price (delayed)
$1.19
Market cap
$64.88M
P/E Ratio
14.88
Dividend/share
N/A
EPS
$0.08
Enterprise value
-$6.79M
Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug-resistant (MDR) bacterial infections and rare diseases.
Highlights
The debt has declined by 21% year-on-year and by 6% since the previous quarter
The gross profit has grown by 37% YoY but it has contracted by 10% from the previous quarter
SPRO's revenue is up by 37% YoY but it is down by 10% from the previous quarter
The P/E is 113% higher than the last 4 quarters average of 7.0
The net income has plunged by 80% from the previous quarter
Key stats
What are the main financial stats of SPRO
Market
Valuations
Earnings
Shares outstanding
54.52M
Market cap
$64.88M
Enterprise value
-$6.79M
Price to earnings (P/E)
14.88
Price to book (P/B)
0.98
Price to sales (P/S)
0.61
EV/EBIT
-1.88
EV/EBITDA
-1.86
EV/Sales
-0.06
Revenue
$106.46M
EBIT
$3.61M
EBITDA
$3.65M
Free cash flow
-$17.54M
Per share
Balance sheet
Liquidity
EPS
$0.08
Free cash flow per share
-$0.32
Book value per share
$1.21
Revenue per share
$1.97
TBVPS
$2.5
Total assets
$135.16M
Total liabilities
$69.65M
Debt
$4.62M
Equity
$65.51M
Working capital
$82.53M
Debt to equity
0.07
Current ratio
2.68
Quick ratio
2.64
Net debt/EBITDA
-19.64
Margins
Efficiency
Dividend
EBITDA margin
3.4%
Gross margin
100%
Net margin
3.3%
Operating margin
-1%
Return on assets
2.2%
Return on equity
4%
Return on invested capital
7.9%
Return on capital employed
4.2%
Return on sales
3.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SPRO stock price
How has the Spero Therapeutics stock price performed over time
Intraday
-0.83%
1 week
-4.8%
1 month
-7.03%
1 year
-1.65%
YTD
-19.05%
QTD
-11.19%
Financial performance
How have Spero Therapeutics's revenue and profit performed over time
Revenue
$106.46M
Gross profit
$106.46M
Operating income
-$1.1M
Net income
$3.51M
Gross margin
100%
Net margin
3.3%
SPRO's operating margin has dropped by 108% since the previous quarter but it has surged by 75% year-on-year
Spero Therapeutics's operating income has plunged by 107% from the previous quarter but it has soared by 65% YoY
The net income has plunged by 80% from the previous quarter
The net margin has dropped by 78% since the previous quarter
Growth
What is Spero Therapeutics's growth rate over time
Valuation
What is Spero Therapeutics stock price valuation
P/E
14.88
P/B
0.98
P/S
0.61
EV/EBIT
-1.88
EV/EBITDA
-1.86
EV/Sales
-0.06
The P/E is 113% higher than the last 4 quarters average of 7.0
The EPS has dropped by 79% year-on-year and by 76% since the previous quarter
The price to book (P/B) is 61% less than the 5-year quarterly average of 2.5 but 9% more than the last 4 quarters average of 0.9
The equity has increased by 22% year-on-year but it has declined by 19% since the previous quarter
SPRO's P/S is 95% below its 5-year quarterly average of 13.4 and 13% below its last 4 quarters average of 0.7
SPRO's revenue is up by 37% YoY but it is down by 10% from the previous quarter
Efficiency
How efficient is Spero Therapeutics business performance
SPRO's ROIC has shrunk by 87% YoY and by 84% QoQ
The return on assets has dropped by 81% since the previous quarter
Spero Therapeutics's ROE has plunged by 81% from the previous quarter
The return on sales has dropped by 80% since the previous quarter
Dividends
What is SPRO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SPRO.
Financial health
How did Spero Therapeutics financials performed over time
SPRO's total assets is 94% higher than its total liabilities
The current ratio has contracted by 33% YoY
SPRO's quick ratio is down by 31% year-on-year and by 16% since the previous quarter
The debt is 93% smaller than the equity
The debt to equity has contracted by 36% YoY but it has grown by 17% from the previous quarter
The equity has increased by 22% year-on-year but it has declined by 19% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.